Anmelden Kostenlos registrieren

Inhibrx Umsatz Q / Q

Was ist das Umsatz Q / Q von Inhibrx?

Umsatz Q / Q von Inhibrx, Inc. ist 233.33%

Was ist die Definition von Umsatz Q / Q?

Das vierteljährliche Umsatzwachstum im Vergleich zum Vorjahr ist die Steigerung des Umsatzes eines Unternehmens im Vergleich zur Leistung des entsprechenden Quartals eines Vorjahres, ausgedrückt in Prozent.

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

Umsatz Q / Q von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Inhibrx

Was macht Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Unternehmen mit umsatz q / q ähnlich Inhibrx